Bristol Myers lymphoma therapy acquired in Celgene deal wins FDA nod February 6, 2021 Auto Bot BioPharma, biopharma nl, Bristol-Myers Squibb, cancer, diffuse large B-cell lymphoma, Healthcare, New York, News, Personalized Medicine, Pharma 0 After some setbacks and delays, the FDA approved Bristol Myers Squibb’s Breyanzi for certain lymphomas. It’s the third CAR T treatment to win the regulatory nod and the first under a new regenerative medicine designation.